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ABSTRACT 
Melanoma is a malignant tumor derived from melanocytes. Once disseminated, it is usually 
highly resistant to chemotherapy and is associated with poor prognosis. We have recently 
reported that T-type calcium channels (TTCCs) are overexpressed in melanoma cells and play 
an important role in melanoma progression. Importantly, TTCC pharmacological blockers 
reduce proliferation and deregulate autophagy leading to apoptosis. Here, we analyze the role 
of autophagy during migration/invasion of melanoma cells. 
TTCC Cav3.1 and LC3-II protein are highly expressed in BRAFV600E compared to NRAS mutant 
melanomas, both in cell lines and biopsies. Chloroquine, pharmacological blockade or gene 
silencing of TTCCs inhibits the autophagic flux and impairs the migration and invasion 
capabilities, specifically in BRAFV600E melanoma cells. 
Snail1 plays an important role in motility and invasion of melanoma cells. We show that Snail1 
is strongly expressed in BRAFV600E melanoma cells and patient biopsies, and its expression 
decreases when autophagy is blocked. These results demonstrate a role of Snail1 during 
BRAFV600E melanoma progression and strongly suggest that targeting macroautophagy and, 
particularly TTCCs, might be a good therapeutic strategy to inhibit metastasis of the most 
common melanoma type (BRAFV600E). 
 
SIGNIFICANCE 
T-type calcium channels (TTCCs) are overexpressed during melanoma progression, but the role 
they play is still unclear. The present study reports an impairment of migration and invasion 
abilities of the most common genetic melanoma subgroup (BRAF/V600E) when subjected to 
pharmacological TTCC blockade. It has been long described that BRAF/V600E melanomas have 
upregulated autophagic flux, and similar results have been observed when autophagy is 
blocked. These findings show that autophagy and TTCC regulation intersect at some point 
which seems to be controlled by Snail1. Therefore, the present work is at the frontier between 
basic and translational science and open new therapeutic strategies.  
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INTRODUCTION  
Cutaneous melanoma is a malignant neoplasm derived from skin melanocytes. Melanoma cells 
have a high ability of local invasion and metastasis, even when arise from very small volume 
tumors (Gray-Schopfer, Wellbrock, & Marais, 2007). Once disseminated, melanoma is highly 
resistant to conventional anticancer treatments and its prognosis is poor (Pollack et al., 2011).  
As melanoma can present in young and medium age adults (Lee et al., 2016; Ríos et al., 2013),  
it  causes disproportionate mortality in such population being responsible of one of the highest 
rate of loss of potential life for adult-onset cancers (Ekwueme et al., 2011). Although available 
therapies for metastatic melanoma have evolved substantially in the last years, especially with 
the introduction of targeted- and immunotherapies (M. Hao et al., 2015), melanoma is still a 
serious health care problem and melanoma cell behavior is an important subject of research.  
Several genetic mutations have been associated to melanoma development and progression. 
Overall, around 40-50% of melanomas carry mutations in the BRAF gene. Of these, 90% bear 
the BRAFV600E mutation (Banzi et al., 2016; Dhomen et al., 2009). About 20% of melanomas 
harbor mutations in the NRAS gene, mostly affecting codon Q61 (Jakob et al., 2012). 
Moreover, many other genetic alterations have been described that confer gain/loss function 
of genes that trigger abnormal signaling pathways like KIT, GNAQ/GNA11, CDKN2A, PTEN, NF1, 
BAP1, among others (Griewank et al., 2014). Some studies advocate that patients with primary 
BRAFV600E or NRAS melanoma have worse survival rate compared to wild-type (WT) BRAF 
melanoma patients (Davies et al., 2002; Long et al., 2011). However it seems that, once 
disseminated, BRAF and NRAS mutation status does not influence survival in 
metastatic melanoma (Carlino et al., 2014). 
The expression of T-type calcium channels (TTCCs) is increased in a number of tumors, where 
they promote cell proliferation (Dziegielewska, Gray, & Dziegielewski, 2014; Macià, Herreros, 
Martí, & Cantí, 2015). Human melanoma cells overexpress Cav3.1 and Cav3.2 isoforms of 
TTCCs, compared with untransformed melanocytes (A Das et al., 2012). Importantly, TTCC 
pharmacological blockers not only reduce the proliferation of melanoma cells, but also trigger 
apoptotic cell death, partially through the activation of caspases (Arindam Das et al., 2013). 
We found that such apoptotic process is preceded by ER stress and blockade of the autophagic 
flux (Arindam Das et al., 2013). Therefore, TTCCs may be valuable therapeutic targets against 
melanoma progression (A Das et al., 2012; Arindam Das et al., 2013; Macià et al., 2015; 
Maiques et al., 2016). 
Macroautophagy (hereafter autophagy) is a housekeeping cell process that plays a significant 
role in tumor progression (Kroemer, Mariño, & Levine, 2010; Mizushima & Komatsu, 2011) and 
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resistance to therapy (Amaravadi, 2011; Corazzari et al., 2015; Ma et al., 2011). Autophagy is 
constitutively induced in melanoma cells, and may be further induced during chemotherapy 
(Corazzari et al., 2015; Arindam Das et al., 2013; Ma et al., 2011). In addition, autophagy 
blockade results in decreased tumor cell migration and invasion (Lu et al., 2016; Mowers, 
Sharifi, & Macleod, 2016; Sharifi et al., 2016). Hence, autophagy modulation is an emerging 
therapeutic strategy also in melanoma.  
Melanoma cell invasion and subsequent metastasis are hallmarks of melanoma dissemination 
(Chin, Garraway, & Fisher, 2006). Snail1 is a major transcription factor that induces epithelial-
mesenchymal transition (EMT) and has been shown to be crucial during tumor progression and 
invasion (Cano et al., 2000; Thiery, 2002). In melanoma cells, Snail1 is up-regulated (Poser et 
al., 2001) and promotes cell motility and invasiveness (L. Hao, Ha, Kuzel, Garcia, & Persad, 
2012; Olmeda, Jordá, Peinado, Fabra, & Cano, 2007). Consequently, downregulation of Snail1 
in melanoma cells reduces tumor growth, metastasis and immunosuppression (Kudo-Saito, 
Shirako, Takeuchi, & Kawakami, 2009; Pearlman, Montes de Oca, Pal, & Afaq, 2017).  
 
RESULTS  
Expression of TTCCs in melanoma cells with different genetic profile.  
We first studied the expression of TTCCs by RT-PCR in a wide range of melanoma cell lines 
bearing different molecular features (Table S1). Different levels and patterns were observed in 
all melanoma cell lines regarding transcripts for Cav3.1 (Figure 1a), Cav3.2 (Figure 1b) and 
Cav3.3 (Figure 1c) isoforms. However, Cav3.1 levels were frequently higher than in 
untransformed melanocytes (HEMn-LP). The expression of Cav3.1 and Cav3.3 mRNA was 
increased in BRAFV600E melanoma cell lines compared to NRASQ61H/K/L/R (Figure 1d- f), 
whereas no significant differences were observed regarding to Cav3.2 mRNA levels (Figure 1e).  
TTCC blockers block basal autophagy in all melanoma cell lines  
Autophagy in melanoma cells is constitutively active (Arindam Das et al., 2013; Maes & 
Agostinis, 2014). To study autophagy, we measured LC3I/II, an autophagic marker (Sahani, 
Itakura, & Mizushima, 2014), by Western blot (WB) in melanoma cell lines. We observed an 
increase of LC3II levels in most of  the BRAFV600E melanoma (Figure 1g). When cells were 
treated with TTCC blockers (Mibefradil (Mib) and Pimozide (Pim)) increased levels of LC3II and 
p62 were detected in BRAFV600E (Figure 1h, S1a) and NRAS (Figure 1i, S1b) melanoma cell 
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lines. This data is suggestive of autophagy blockade at a step following autophagosome 
biogenesis. Treatment of the melanoma cell lines with Chloroquine (CQ), that prevents the 
fusion of autophagosomes (AP) with lysosomes (Boya et al., 2005), led to similar increases of 
LC3II and p62 proteins in all cell lines (Figure 1j-1k, S1c-d). To further confirm these changes on 
autophagy observed by western blot, LC3B immunofluorescence (IF) was used as a marker for 
AP (Mizushima, Yoshimori, & Levine, 2010). A significant increase of AP puncta was observed 
both in M3 (BRAFV600E) and in Skmel-147 (NRASQ61R) cell lines when they were subjected to 
Mib or CQ treatment (Figure 1l). Moreover, addition of Chloroquine to Mibefradil-treated 
cultures did not further increase the levels of p62 and LC3II (Figure S1e). Taken together, these 
results indicate that TTCC blockers block autophagy, regardless of the specific mutation 
present in melanoma cell lines. 
Autophagy blockade inhibits collective migration of BRAFV600E melanoma cell lines 
Cell migration is a key process during melanoma metastasis. We assessed the effect of TTCC 
blockers on melanoma migration using a wound healing assay that measures collective 
migration. Both TTCC blockers decreased the percentage of BRAFV600E melanoma cells 
migrating into the wound (Figure 2). Consistently, treatment of BRAFV600E cell lines with CQ 
also reduced the migration rate (Figure 2a-b, S2a-c). Interestingly, migration was unaffected in 
NRAS mutant melanoma cells treated with TTCC blockers or CQ (Figure 2c-d, S2d-f) even when 
autophagy was blocked. 
Using time-lapse microscopy, we found slower migration of BRAFV600E cells (M3 and M249) 
treated with Mibefradil or CQ when compared to control, even after 8h treatment (Figure S3a-
b). Furthermore, the healing speed of BRAFV600E cells decreased after treatment with either 
Mibefradil or CQ (Figure 2a-b, S3a-b and movies S1-3 (M3)). 
In contrast, Mibefradil or CQ treatments did not affect neither the percentage of wound 
healing nor the healing speed of the NRAS mutant cells (Figure 2c-d, S3c-d and movies S4-6 
(Skmel147)).  
To further study how autophagy inhibition affects melanoma cell migration, we knocked down 
Atg5, an autophagy-related protein required for autophagosome formation (Pyo et al., 2005), 
by lentivirus-driven shRNA. Silencing of Atg5 induced a decrease of LC3II in both BRAFV600E 
and NRAS mutant cell lines (Figure 2e). It also decreased the migration of BRAFV600E (M3) 
melanoma cells (Figure 2f), but not of the NRAS mutant cells (WM-1366) (Figure 2g). 
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Overall, these results show that the BRAFV600E cell lines are less motile after treatment with 
Mibefradil, Pimozide, CQ, or silencing Atg5 expression, suggesting that TTCC blockers inhibit 
the migration of BRAFV600E cells by blocking the autophagic process. 
Mibefradil and CQ inhibit single cell migration in BRAFV600E melanoma cells.  
To analyze the effect of TTCC blockers on cell migration independent of cell-cell interactions, 
we studied single cell random migration by time-lapse. For these experiments, melanoma cells 
were plated at lower density compared to previous approaches and Mibefradil and CQ 
concentrations were halved (12.5μM and 5μM, respectively) in order to maximize cell survival 
and also halted basal autophagy (Figure S4). Analysis of individually tracked cells revealed that 
the accumulated distance and the migration speed of BRAFV600E cells were significantly 
reduced when treated with Mibefradil or CQ (Figure 3a-b, movies S7-9 (M3)). In line with our 
findings, neither the distance nor the velocity was significantly affected by either treatment in 
NRAS mutant cells (Figure 3c-d, movies S10-12 (Skmel147))  
This results show that Mibefradil and CQ decrease single cell migration in BRAFV600E 
melanoma cells by blocking the autophagic flux. 
Autophagy blockade inhibits invasion of BRAFV600E melanoma cell lines.  
We next investigated the effect of TTCC blockers on the invasive capacity of melanoma cells. 
Treatment with Mibefradil or CQ for 24h inhibited the invasive capacity of BRAFV600E 
melanoma cells (Figure 4a-b). Similar results were observed upon 24h treatment with 
Pimozide (Figure S5a-b). On the contrary, neither TTCC blockers nor CQ affected the invasion 
ability of the NRAS mutant cell lines (Figure 4a-b). Silencing Atg5 expression (Figure 2e) also 
reduced the invasive capacity of BRAFV600E (M3) melanoma cells. Again, differences were not 
significant in NRAS (WM-1366) mutant cells (Figure 4c-d). These results indicate that 
autophagy inhibition or blockade might be used to control the invasive potential of BRAFV600E 
melanoma cells.  
Gene silencing of TTCCs reduces the invasion ability of BRAFV600E melanoma cell lines 
Previously we showed that TTCC silencing leads to autophagy impairment that mimics the 
effect of TTCC blockers (Arindam Das et al., 2013). To investigate the possible involvement of 
TTCCs in the invasion capacity of BRAFV600E melanoma cells, we knocked down TTCCs in M3 
cells using lentiviral constructs carrying shRNA specific to Cav3.1 and Cav3.2 (Figure S5c-e). 
When measured in Transwell assays, both TTCC silencing inhibited the invasive capability of 
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M3 cells (Figure 4e-f). An increase of p62 and LC3II protein levels was observed when either 
Cav3.1 or Cav3.2 isoforms were silenced (Figure S5f), thus mimicking the effects of Mibefradil, 
Pimozide or CQ. These results indicate that TTCCs leads to induce invasion in BRAFV600E 
melanoma cell lines.  
Analysis of expression of TTCCs in biopsies from melanoma patients 
To extend our observations to the clinical settings, we used a cohort of 33 primary and 28 
metastatic melanomas biopsies. Such cohort was divided in two main groups according to their 
BRAF genetic status (mutant BRAFV600E/K vs BRAFWT) analyzed by PCR sequencing (Table S2). 
The expression levels (histoscore) of TTCCs (Cav3.1 and Cav3.2) and LC3 were assessed by IHC. 
All melanoma samples bearing BRAFV600E/K gene mutations showed a higher 
immunoexpression of Cav3.1 compared to the WT BRAFWT cohort (Figure 5a-b), thus 
confirming our previous results (Maiques et al., 2016). In contrast, Cav3.2 immunoexpression 
did not show significant differences between the two groups (Figure 5c-d). 
We additionally checked whether the mutation status of melanoma cells had an impact on 
macroautophagy, by quantifying the expression of LC3. The immunoexpression of LC3 was 
elevated in the BRAFV600E/K biopsies compared to the BRAFWT group (Figure 5e-f), 
suggesting an enhanced basal autophagy of BRAFV600E/K biopsies.  
Snail1 expression is higher in BRAFV600E melanomas and decreases upon autophagy 
blockade  
Snail1 plays several roles in cell migration and EMT process (Cano et al., 2000). To understand 
if autophagy was regulating cell migration and invasion controlling Snail1 we quantified the 
expression of Snail1 in our melanoma cell lines by WB and RT-PCR, and found that both protein 
(Figure 6a) and mRNA (Figure 6b) levels were augmented in BRAFV600E, compared to NRAS 
mutant cells.  
Snail1 was reduced in BRAFV600E cell lines that were treated with TTCC blockers (Figure 6c), or 
subjected to gene silencing of TTCCs (Figure 6f). In addition, treatment of BRAFV600E cells with 
CQ (Figure 6d) or gene silencing of ATG5 (Figure 6e) consistently decreased the levels of Snail1, 
showing that the expression of Snail1 was related to the status of the autophagic flux. It has 
been shown that Snail1 plays an important role in melanoma progression (L. Hao et al., 2012; 
Olmeda et al., 2007). Indeed, Snail1 knockdown impaired cell migration and invasion (Figure 
6g-h) of BRAFV600E cells, mimicking the effect of TTCC blockers and CQ. To further study 
whether Snail1 can modulate autophagy in melanoma cells, we stably overexpressed Snail1 
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(PLX-Snail1) in an NRAS mutant cell line, SKMEL147. Snail1 overexpression induced an increase 
in p62 and LC3I/II levels compared to PLX-empty vector cells (Figure 6i). Moreover, 
immunofluorescence of LC3B showed a slightly increase of AP puncta when Snail1 was 
overexpressed and such increase was higher after a short treatment of CQ, suggesting a 
possible increase of basal autophagy. In addition, Mibefradil treatment increased LC3B positive 
puncta in cells, independently on Snail1 expression (Figure 6j).  
To investigate whether Snail1 takes part in migration/invasion process during modulation of 
autophagic flux, we treated Snail1-overexpressing cells with Mib or CQ. There was an 
impairment of migration (Figure 6k) and invasion (Figure 6m) in Snail1-overexpressing cells 
when autophagy was blocked. Furthermore, Mibefradil decreased single cell migration in 
Snail1-overexpressing cells (Figure 6l). These results suggest that Snail1 could be essential to 
impair migration/invasion when autophagy is blocked, particularly by targeting TTCCs. To 
complement these approaches, we used the publicly available database TCGA and found that 
Snail1 expression was increased in melanoma biopsies of patients harboring BRAFV600E 
mutation, compared to that BRAFWT (Figure 6n). Cell migration and invasion are key steps 
during metastatic dissemination; therefore, we performed Snail1 IHC analysis in metastatic vs 
primary melanoma biopsies. Snail1 nuclear staining (active form) was significantly higher in 
metastatic compared to primary lesions only in patients harboring BRAFV600E/K mutations 
(Figure 6o). Moreover, we observed a higher Snail1 score in BRAFV600E/K metastasis, 
compared to BRAFWT metastatic tumors. These results indicate an important role of Snail1 
during metastatic spread of BRAFV600E melanomas.  
 
DISCUSSION  
We have previously shown that the immunoexpression of TTCCs increases gradually from 
melanocytes to primary and metastatic melanoma biopsies and relates to poor prognosis 
(Maiques et al., 2016). Here we describe (in both cultured cell lines and FFPE melanoma 
biopsies) that the Cav3.1 isoform is upregulated in BRAFV600E melanomas, which is 
accompanied by increased levels of LC3-II proteins, compared to NRAS mutant. BRAFV600E 
melanoma cells display an enhanced autophagy (Armstrong et al., 2011; Corazzari et al., 2015; 
Giglio, Fimia, Lovat, Piacentini, & Corazzari, 2015; Maddodi et al., 2010). Thus, autophagy 
inhibition could be a therapeutic tool to enhance the antitumor activity of BRAF inhibitors. 
Furthermore, this strategy may also prevent tumor resistance, as autophagy preceded by ER 
stress is a likely mechanism of resistance to BRAF inhibitors in melanoma (Ma et al., 2014). In 
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support of this, combination of Atg5 knockdown and MEK inhibition increases cell death in 
vemurafenib-resistant melanoma cell lines (Martin et al., 2015).  
Importantly, autophagy also plays a role in melanoma metastasis. For instance, Xie et al. 
showed that autophagy inhibition by deletion of Atg7 or treatment with CQ suppresses 
melanoma tumor growth and increases survival of mice driving oncogenic BRAFV600E 
expression and Pten-deficiency in melanocytes (Xie, Koh, Price, White, & Mehnert, 2015). 
Furthermore, CQ reduces tumor growth and impairs melanoma cell invasion and metastasis 
(Maes et al., 2014). In addition, Sharifi and co-workers revealed that autophagy inhibition 
reduces cell migration and invasion (in breast cancer and melanoma) and attenuates the 
induction of metastasis by disrupting the focal adhesion turnover (Sharifi et al., 2016). We 
studied the role of autophagy in the migration/invasion of BRAFV600E and NRAS melanomas. 
Our results demonstrate that TTCC blockers, Mibefradil and Pimozide, impair migration and 
invasion of BRAFV600E cells, an effect exerted also by CQ or Atg5 knockdown. In contrast, cell 
motility in vitro is largely unaffected by autophagy inhibition in NRAS melanoma cell lines.  
We evaluated Snail1 expression, a master transcription factor that induces EMT and invasion in 
melanoma cells (L. Hao et al., 2012; Olmeda et al., 2007). Our results indicate that Snail1 
expression is higher in BRAFV600E melanoma cells compared to BRAFWT cells. Interestingly, 
Snail1 levels decrease when autophagy is blocked by chloroquine or by TTCC blockers, thus 
inhibiting migration and invasion. Furthermore, when we overexpressed Snail1 in NRAS 
mutant melanoma cell line, we show an impairment of migration/invasion abilities when 
autophagy is blocked. Therefore, autophagy appears to regulate cell motility through different 
mechanisms depending on the cell type and context (Kenific, Thorburn, & Debnath, 2010).  
BRAF and NRAS mutations are mutually exclusive in melanoma (Davies et al., 2002). Common 
to them is the direct or concomitant hyperactivation of signaling pathways like MEK-ERK and 
PI3K (Griewank et al., 2014; Vu & Aplin, 2016). However, our studies indicate that BRAFV600E 
and NRASQ61 activate distinct cellular mechanisms related to melanoma progression. It has 
been shown that activation of ERK, the main target of BRAFV600E, is an upstream signaling 
mechanism responsible for high constitutive Snail1 expression in melanoma cells (Massoumi et 
al., 2009). In addition, Snail1 knockdown disrupts tumor growth and impairs melanoma 
progression and migration, similar to results reported here (L. Hao et al., 2012; Massoumi et 
al., 2009). In BRAFV600E melanomas, the phosphorylation of Cortactin and the exocyst subunit 
Exo70 upon ERK activation, which regulates the secretion of matrix metalloprotease-2, 
appears as a relevant mechanism for cell migration (Lu et al., 2016; Sandri et al., 2016).  
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Our findings reveal an unknown link between autophagy and Snail1 expression that regulates 
the migration and invasion of BRAFV600E melanoma cells. It has been described that p62 
modulates the stability of Snail1, a mediator of TGFβ/Smad signaling, through its UBA domain 
(Bertrand et al., 2015). New evidences indicate that autophagy is not only involved in the 
intracellular degradation of damaged proteins, but also plays an important role in protein 
secretion (Kraya et al., 2015; Narita et al., 2011). In addition, autophagy-related secretion 
affects the tumor microenvironment and reflects the autophagy dynamics of tumor cells 
(Kraya et al., 2015). A recent paper further revealed that the TGFβ/Snail signaling pathway 
induces EMT-like process in a paracrine manner in melanoma (Lv et al., 2017). Moreover, 
knockout mice of GABARAP, an Atg8/LC3 family member implicated in the induction of 
autophagy, showed reduced amounts of TGFβ in serum and inhibition of tumor initiation and 
progression, through the enhancement of both anti-tumor immunity and cell death signaling 
(Salah et al., 2016). Therefore, all these data may suggest that the secretion of TGFβ through 
autophagy could lead to increased expression of Snail1, during the induction of 
migration/invasion of BRAFV600E melanoma cells. Nevertheless, the mechanism by which 
Snail1 levels decrease upon autophagy blockade in BRAFV600E melanoma cells requires 
further investigation. A possibility would be that Snail1 proteasomal degradation (Muqbil, Wu, 
Aboukameel, Mohammad, & Azmi, 2014) is deregulated after autophagy blockade. 
In conclusion, our findings indicate that BRAV600E melanoma cells display higher levels of the 
Cav3.1 TTCC and an increased basal autophagy, compared to other types of melanoma cells. In 
addition, the migration and invasion capabilities of BRAFV600E cells are sensitive to the 
genetic ablation or pharmacological inhibition of autophagy and depend on Snail1 levels. Thus, 
chemotherapeutic strategies targeting TTCCs and/or autophagy appear especially suitable to 
tackle metastasis in the most common type of melanoma. 
 
MATERIALS AND METHODS  
Cell lines 
Twelve human malignant melanoma cell lines were used and sequenced (BRAF or NRAS 
mutation) (Table S1). For cell culture conditions see Supplemental Experimental Procedures.  
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Real-time RT-PCR 
Total RNA was extracted with a SurePrep Total RNA Isolation kit (Applied Biosystems). Total 
RNA 2µg was used to generate cDNA with Taqman technology from Applied Biosystems. 
Relative expression was calculated using the comparative ΔΔCT method. Levels of both calcium 
channels were expressed as fold change relative to mRNA from melanocytes (HEMn-LP). 
Probes used are detailed in Supplemental Experimental Procedures. 
Western blot 
Melanoma cells were lysed in 2% sodium dodecyl sulfate (SDS), 125 mM Tris–HCl, pH 6.8. 
Western blot was conducted as described (Arindam Das et al., 2013). The antibodies used are 
detailed in Supplemental Experimental Procedures. 
Immunofluorescence 
Melanoma cells were fixed with 100% methanol (10min 4ºC), and blocked with 0.2% Triton X-
100 (1h RT). Cells were incubated with anti-MAP1LC3B (1:200, rabbit polyclonal, Cell Signaling 
Technology, 4ºC o/n).   
Lentiviral infection 
The lentiviral vector containing the sequences of the shRNA of Cav3.1 (TRCN0000044239), 
Cav3.2 (TRCN0000044209), Snail1 (TRCN0000063818) and control (shRNA SCR; 
MFCD07785395) were from Sigma. The lentiviral vector comprising the sequence of shRNA of 
ATG5 was kindly provided by Yeramian A. We used pLX304-Snail1 (NM_005985.3) recombinant 
lentiviral plasmid to overexpress Snail1 in melanoma cells. See Supplemental Experimental 
Procedures for shRNA sequences and lentiviruses generation. 
Wound healing 
A confluent monolayer of cells was scratched with yellow tip. Thereafter, cells were treated 
and we captured an image of the scratch at time 0h and after 24h to calculate the percentage 
of the wound filled by cells. For time-lapse wound healing assay movies see Supplemental 
Experimental Procedures. 
Single cell migration assay 
Cells were plated at low density (6000 cell/cm2) to minimize cell-cell interactions. Cells were 
treated and capturing an image every 20 minutes for 20h. Cells were tracked using ImageJ 
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plugin and the accumulated distance (µm) and the velocity (µm/h) of the single cells were 
evaluated using Chemotaxis and Migration Tool (Ibidi). 
Transwell experiments 
We first treated the cells during 24h. Then, cells were tripsinized and plated in the upper 
chamber of the Transwell (8µm pore, Falcon) coated with Matrigel in serum-free medium. We 
used 10% of FBS as a chemoattractant. After 24h, cells were fixed with paraformaldehyde 4% 
and stained with Hoechst (5µg/ml). Finally, cells were pictured under an epifluorescence 
microscope (Leica), before and after the cotton swap and we counted (ImageJ) to have the 
percentage of the migrated cells.  
Tissue Microarray and Immunohistochemical study 
One tissue microarray (TMA) was constructed from 61 formalin-fixed, paraffin-embedded 
(FFPE) melanoma tumors (primary and metastatic Table S2). Assessment of TTCC 
immunostaining and LC3 were done as detailed in (Maiques et al., 2016). The antibodies used 
and IHC protocol of Snail1 and scoring see Supplemental Experimental Procedures. 
In silico studies 
SNAI1 expression was analyzed in 243 human melanoma samples (109 BRAFV600E, 134 
BRAFWT) from The Cancer Genome Atlas (TCGA) database (http://cancergenome.nih.gov/). 
Only samples with greater than 70% tumor cell content were considered. Normalized mRNA 
expression data were downloaded from cBioPortal (Cerami et al., 2012; Gao et al., 2013) and 
analyzed using GraphPad Prism. 
Ethics statement 
Studies using human samples were approved by the Ethics Committee on Clinical Investigation 
of the Hospital Universitari Arnau de Vilanova (HUAV, Lleida, Spain), and all patients gave their 
informed consent. 
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism software. All data were expressed as 
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LEGEND FOR FIGURES 
Figure 1: TTCCs are expressed in melanoma cell lines and TTCC blockers inhibit 
macroautophagy. qRT-PCR of a) Cav3.1, b) Cav3.2 and c) Cav3.3 in BRAFV600E or NRAS 
mutated melanoma cell lines and normalized to GAPDH expression. The mRNA levels from 
melanocytes (HEMn-LP) are shown for comparison. Comparison of the mRNA levels of (d) 
Cav3.1, (e) Cav3.2 and (f) Cav3.3 between cell line groups. The statistical analysis used was 
Mann Whitney test, (*p<0.05; n.s non-significant). g) Analysis of LC3I/II by WB from total 
protein lysates. WB analysis to test p62 and LC3 protein levels from h) BRAFV600E and i) NRAS 
mutant melanoma cells exposed to Mibefradil (Mib, 10µM) and Pimozide (Pim, 10µM) for 24h. 
j) BRAFV600E and k) NRAS mutant melanoma cells treated with CQ (25µM) for 24h.  β-actin 
was used as a loading control. l) Immunofluorescence images and graphs of LC3B positive 
puncta in M3 (BRAFV600E) and Skmel-147 (NRASQ61R) cell lines in untreated, Mib or CQ 
treatments. AP: Autophagosomes. Statistical analysis was performed using ANOVA and 
Bonferroni tests (*p<0.05; **p<0.01; ***p<0.001; n.s., non-significant). 
Figure 2: Blocking macroautophagy inhibits migration of BRAFV600E melanoma cells. 
Representative pictures and graphs of wound healing assay of (a-b) BRAFV600E and (c-d) NRAS 
mutant cells treated with Mibefradil (10µM, Mib), Pimozide (10µM, Pim) and CQ (25µM) 
during 24h. Panels on the left of each cell line represent the percentage of wound closure as a 
result of at least three independent experiments. Panels on the right represent the healing 
speed (µm2/h) of cells after treatment compared to the control analyzed by estimated linear 
regression. e) WB analysis shows the downregulation of ATG5 and LC3I/II levels. β-actin was 
used as a loading control. Percentage of wound closure in (f) M3 and (g) WM-1366 cells control 
(Vector) or upon ATG5 silencing (shATG5). Statistical analysis was performed using ANOVA and 
Bonferroni tests or t-test (*p<0.05; **p<0.01; ***p<0.001; n.s., non-significant).  
Figure 3: Mibefradil and CQ reduce single cell migration in BRAFV600E melanoma cells. Cell 
tracking analysis was carried out for 24h at a rate of 1 frame per 20 minutes. The total 
accumulated length migrated (µm) and the migration speed (µm/h) of treated and untreated 
cells was analyzed in (a-b) BRAFV600E and (c-d) NRAS mutant cells. Around 25 significant 
tracks of control and treated cells were plotted in the trajectory graphs in the right side of the 
figure. Trajectories of each group of cells were standardized to all begin at the same starting 
point. The statistical analysis used was ANOVA and Bonferroni tests (*p<0.05; **p<0.01; 
***p<0.001). 
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Figure 4: Autophagy blockade and silencing of Cav3.1 and Cav3.2 reduce cell invasion in 
BRAFV600E melanoma cell lines. a) Representative images of nuclear Hoechst staining after 
the cotton swap (microscopic field x10).  b) Percentage (%) of cells that invaded the Matrigel 
after treatment with Mib and CQ compared to the control. c-d) M3 and WM-1366 cells were 
infected with control lentiviruses (Vector, control) or lentiviruses expressing a shRNA of ATG5. 
c) Representative nuclear Hoechst staining of cells that invaded the Matrigel and (d) graph 
representing the % of invasive cells. e) Representative images of nuclear Hoechst staining after 
the cotton swap in M3 cell line infected with shRNA of Cav3.1 and Cav3.2 compared to control 
(Vector, scrambled shRNA) and f) Percentage (%) of invaded cells. Pictures magnification 10x. 
The statistical analysis used was ANOVA and Bonferroni test (*p<0.05; **p<0.01; ***p<0.001; 
n.s., non-significant). 
Figure 5: Differential expression of Cav3.1, Cav3.2 and LC3 in melanoma depending on BRAF 
mutational status. Differential immunoexpression (Histoscore, mean±SD) and representative 
images of the immunostaining for (a-b) Cav3.1 (mean HS BRAFV600E/K vs WT: 85 vs 37,5), (c-
d) Cav3.2 (mean HS BRAFV600E/K vs WT:147.5 and 146.6) and (e-f) LC3 (mean HS 
BRAFV600E/K vs WT: 84 vs 44,6) analyzed in BRAF mutant melanoma biopsies compared to 
BRAFWT melanoma samples. Pictures magnification 20x. The statistical analysis used was 
Mann Whitney test (*p<0.05; **p<0.01; ***p<0.001; n.s., non-significant). 
Figure 6: BRAFV600 melanomas express higher levels of Snail1, which decrease upon 
autophagy blockade. a) WB and b) mRNA Snail1 levels between BRAFV600E and NRAS 
mutated melanoma cell lines. WB analysis of Snail1 in BRAFV600E and NRAS mutant cells 
treated with (c) Mibefradil, Pimozide or (d) CQ. WB analysis of Snail1 in BRAFV600E cells 
silenced for (e) ATG5, (f) Cav3.1, Cav3.2 and (g) Snail1. (g) Wound healing assay and (h) 
Transwell assay of BRAFV600E after Snail1 silencing vs control cells (vector). i) WB analysis of 
LC3I/II and P62 in PLX-Snail1 vs PLX-vector cells. Endogenous immunofluorescence of LC3B 
when cells were treated with (j) Chloroquine (CQ, 3h) or Mibefradil (Mib, 24h). k) Wound 
healing assay, (l) Single Cell migration assay and (m) Transwell assay of PLX-Snail1 vs PLX-
vector cells treated with (k,m,) Mibefradil 10µM or (l) 5µM and (k) CQ 25µM during 24h. 
Statistical analysis was performed using ANOVA and Bonferroni tests (*p<0.05; **p<0.01; 
***p<0.001; n.s., non-significant).  (n) SNAI1 expression in BRAFV600E and BRAFWT melanoma 
samples using normalized mRNA expression data from TCGA database. o) Graph and 
representative images (magnifications 10x and 40x) of nuclear 4-tiered (0-3) score 
immunostaining of Snail1 in biopsies with BRAF characterized mutation. The statistical analysis 
used was Mann Whitney test (*p<0.05; **p<0.01; ***p<0.001; n.s., non-significant). 
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